

Anti-CEACAM5/CEA/CD66e Antibody (Tusamitamab)

Introduction

Tusamitamab is an IgG1 monoclonal antibody targeting CEACAM5. Tusamitamab is used to synthesize Tusamitamab ravtansine (SAR408701), a first-in-class humanized antibody-active molecule conjugate (ADC) combining Tusamitamab and DM4, a potent maytansine derivative.

Product parameters

Alternative Names	SAR-408377
Target Accession	P06731
Target	CEACAM5 / CEA / CD66e
CAS number	2349294-95-5
Molecular Weight	144.76 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human CEACAM5 His at 2 ug/mL can bind Anti-CEACAM5/CEA/CD66e Antibody (Tusamitamab), EC50=0.00402 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

